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Innate lymphoid cells (ILCs) are tissue resident cells with organ-specific properties.
Here, we show that the central nervous system (CNS) encompasses ILCs. In particular,
CD3−NK1.1+ cells present in the murine CNS comprise natural killer (NK) cells, ILC1s,
intermediate ILC1s (intILC1s) and ex-ILC3s.We investigated the properties of CNS-ILC1s
in comparison with CNS-NK cells during steady state and experimental autoimmune
encephalomyelitis (EAE). ILC1s characteristically express CXCR3, CXCR6, DNAM-1,
TRAIL, and CD200R and display heightened TNF-α production upon stimulation. In
addition, ILC1s express perforin and are able to degranulate, although in a lesser
extent than NK cells. Within the CNS compartments, ILC1s are enriched in the choroid
plexus where very few NK cells are present, and also reside in the brain parenchyma
and meninges. During EAE, ILC1s maintain stable IFN-γ and TNF-α levels while in
NK cells the production of these cytokines increases as EAE progresses. Moreover,
the amount of ILC1s and intILC1s increase in the parenchyma during EAE, but in
contrast to NK cells, they show no signs of local proliferation. The upregulation in the
inflamed brain of chemokines involved in ILC1 migration, such as CXCL9, CXCL10,
and CXCL16 may lead to a recruitment of ILC1s from meninges or choroid plexus
into the brain parenchyma. In sum, CNS-ILC1 phenotype, distribution and moderate
inflammatory response during EAE suggest that they may act as gatekeepers involved
in the control of neuroinflammation.
Keywords: innate lymphoid cells (ILCs), ILC1s, natural killer (NK) cells, central nervous system (CNS), experimental
autoimmune encephalomyelitis (EAE), mouse
INTRODUCTION
Innate lymphoid cells (ILCs) are tissue resident cells (1) that contribute to tissue homeostasis
and react early to local inflammatory events [reviewed in (2)]. The long-known conventional
natural killer (NK) cells are now categorized as cytotoxic ILCs, which share phenotypical and
functional similitudes with helper-like ILC1s (3). Although ILC1s and NK cells develop from
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different precursor cells (4, 5), both express the T-box family
transcription factor T-bet and secrete type I cytokines, such as
interferon-γ (IFN-γ). Apart from to T-bet, NK cells express and
depend on the transcription factor Eomesodermin (Eomes) for
their development (6, 7). Before the formal definition of ILCs
(3), ILC1s and NK cells were often confounded and evaluated
as a unique cell population due to their similar phenotype and
function, i.e., their primary role in protecting the host against
intracellular infections and cancer. Classically, NK cells were
defined in the mouse as CD3-negative cells that express the
natural cytotoxicity receptor (NCR) NKp46 and NK1.1 (8–10);
receptors that are also expressed on ILC1s and a subset of ILC3s
(5, 11). However, a particular expression pattern of integrins
can aid in the distinction between these two ILC types. While
CD3−NK1.1+/NKp46+ circulating or splenic NK cells express
the α2 integrin CD49b (DX5 antigen) (12), ILC1s express the
α1 or αE forms (CD49a and CD103, respectively), and the lectin
CD69, which contribute to cell retention into the tissues (13–15).
Although, in the last years, the phenotype and role of
the ILC subsets in different organs have been intensively
investigated, very little is known about the presence of ILCs in
the central nervous system (CNS) or about their implication in
neuroinflammatory diseases, such as multiple sclerosis (MS). In
contrast, the role of NK cells has been widely studied in MS
patients and its animal model, the experimental autoimmune
encephalomyelitis (EAE). We and others have shown evidence
for deficient NK cell activity in patients with MS, suggesting
that NK cells may have a protective, disease-limiting role in
neuroinflammation (16–19). In the EAE model, NK cells can
have both detrimental (20, 21) and beneficial (22–24) roles
depending on the NK cell maturation stage and disease stage
investigated. In this line, we have recently shown that the mature
CD11b+ NK cell subset is more cytotoxic toward autoreactive
T cells than the immature CD11b− NK cell subset and that
the chemokine receptor CX3CR1 mediates the migration of
mature NK cells into the CNS, contributing to the control of
neuroinflammation during EAE (25). Additionally, we observed
that a proportion of immature NK cells is present in the brain
parenchyma in steady state and during neuroinflammation;
however, whether this immature population is recruited from the
periphery or whether they represent a CNS-resident ILC subset
remains unclear. We hypothesized that bona fide ILC1s might
be concealed among the phenotypically “immature NK cells.”
Therefore, in the present study, we aimed to characterize the
innate NK1.1+ (NKp46+) cells of the CNS.
We show that the NK1.1+ cells present in the healthy
murine CNS include ILC1s, intILC1s and NK cells but not
ILC3s. We characterized the phenotypic profile of ILC1s in
comparison with NK cells identifying key ILC1 markers and
investigated their presence in the different CNS compartments.
In addition, we analyzed the dynamics of the different group
1 ILCs during neuroinflammation using the EAE model.
The particular phenotype and dynamics of CNS-ILC1s at
steady state and inflammation highlight their potential function
as neuroprotective, gatekeeper and anti-inflammatory agents,




WT female C57BL/6 mice were obtained from the Research
Institute for Experimental Medicine (FEM) of the Charité
(Berlin, Germany) and kept on a 12:12 h day:night cycle with
ad libitum access to food and water. Rorc-CreTg; Rosa26RRFP/+
mice and RORc-GFP mice were provided by C. Romagnani.
All animal experiments were approved by the regional animal
study committee of Berlin (Landesamt für Gesundheit und
Soziales) and performed in accordance to national and
international guidelines.
EAE Induction
Active EAE was induced in 8–12 weeks old female C57BL/6 mice
as previously described (25). In brief, mice were immunized by
a subcutaneous injection of 200 µl of myelin oligodendrocyte
glycoprotein peptide 35–55 (MOG35-55) (Pepceuticals,
Leicester, UK) emulsified in complete Freund’s adjuvant
(Difco Laboratories, USA) containing 800 µg Mycobacterium
tuberculosis H37Ra (Difco). Pertussis toxin (200 ng, Sigma–
Aldrich) was administered intraperitoneally at the day of
immunization and 48 h later. Clinical symptoms were monitored
daily and scored as follows: 0, no symptoms; 0.5, tail weakness;
1, lack of tail tone, 1.5, no righting reflex: 2, hind-limb weakness;
2.5, partial hind-limb paralysis; 3, total hind-limb paralysis; 3.5,
ascending fore-limb paralysis. The mice were sacrificed when a
score>3 was reached.
Preparation of Single Cell Suspension for
Flow Cytometry
Mice were euthanized under anesthesia and perfused with 60ml
of cold PBS. Tissue were collected on ice and immediately
processed, blood was collected in tubes with 2mM EDTA at
room temperature. In brief, the CNS (brain and spinal cord) was
mechanically homogenized with a syringe plug though a 70µm
cell strainer (Corning) and washed with RPMI 1640 medium
(Gibco) supplemented with 10% fetal calf serum (FCS) and
antibiotics. The myelin rich cell suspension was resuspended
in 37% Percoll (Sigma-Aldrich) and the lymphocytes were
collected from the pellet after centrifugation at 2,800 g. Single
cell suspension of spleen and lymph nodes were obtained by
homogenizing the tissue though a 100µm cell strainer, in the
case of spleen and blood, erythrocytes were lysed for 10min
with 0.15M ammonium chloride and washed. Liver lymphocytes
were enriched after mechanical dissociation and homogenization
through a 100 µl cell strainer by centrifuging in a 37.5%
Percoll solution.
The meninges and CP was removed from the same mouse
after a thorough perfusion with cold PBS. In brief, the ventral
side of the skull was carefully removed to expose the brain.
The brain was removed and placed in a petri dish with cold
PBS and the CP was removed under a dissecting microscope by
opening the fourth, third and lateral ventricles, consecutively,
and carefully detaching the CP with small forceps. In parallel,
the dural meninges were peeled off from the interior side of
the skull cap after scoring the edge of the skull 360◦ with
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Dumont # 5 forceps. Each tissue was kept in separate tubes with
medium on ice. The brain was processed as stated above. The
CP was dissociated by pipetting it through a 75µm nylon mesh.
The meninges were digested 20min in 2 mg/ml DNAse (Sigma
Aldrich #DN25) + 2.8 mg/ml collagenase from Clostridium
histolyticum (Sigma Aldrich #C2139) and passed through a
75µm nylon mesh following a washing step and cell staining.
Flow Cytometry
Flow cytometry staining was performed at 4◦C in PBS containing
0.5% BSA. Fc receptors were blocked by incubating 15min
with anti-mouse CD16/CD32 (clone 2.4G2, BD Biosciences),
afterwards, monoclonal anti-mouse antibodies were added and
incubated for 20min. For intracellular and intranuclear staining,
the FoxP3 transcription factor staining buffer set (Invitrogen)
was used to fix and permeabilize the cells according to the
manufacturer’s instructions. The following antibodies were
used: CD3-Pacific Blue (clone 500A2), CD11b-APC/Cy7 (clone
M1/70), RORγt-Brilliant Violet 421 (clone Q31-378) from BD
Biosciences; CD49b-PEDazzle 594 (clone DX5), DNAM-PE
(clone 480.1), CXCR3-Brilliant Violet 510 (clone CXCR3-173),
CCR7-Alexa Fluor 488 (clone 4B12), CCR6-PE/Cy7 (clone 29-
2L17), CD127-PE (clone A7R34), CD122-biotin (clone TM-β1),
TRAIL-biotin (clone N2B2), c-Kit-Brilliant Violet 605 (clone
ACK2), CD103-biotin (clone 2E7), CD90.2-Alexa Fluor 700
(clone 30-H12), CX3CR1-PerCP/Cy5.5 (clone SA011F11), Tbet-
Brilliant Violet 711 (clone 4B10), Eomes-PE/eFluor 610 (clone
Dan11mag), CD200R-PE (clone OX-110), Granzyme B-Alexa
Fluor 700 (clone QA16A02) and Perforin-PE (clone S16009A)
from Biolegend; CD45-FITC (clone 30-F11), CD27-PE/Cy7
(clone LG.7F9), Ki67-PerCP/eFluor 710 (clone SolA15), CXCR6-
PE (clone DANID2), IFNγ-PE (clone XMG1.2) and TNFα-
PerCP/eFluor 710 (clone MP6-xt22) from eBioscience; NK1.1-
APC (clone PK136), CD49a-PE/Vio 770 (clone REA493), CD69-
PerCP/Vio 700 (clone HI.2F3), and Tbet-PE/Vio 615 (clone
REA102) from Miltenyi Biotec. 7-AAD or the Live/Dead fixable
cell death stain from Invitrogen were used for dead cell exclusion.
Sample acquisition was performed in a BD Fortessa Flow
Cytometer (BD Biosciences). Compensation and data analysis
was performed in FlowJo (version 10.4, Treestar) software.
Gating of populations were defined with fluorescence minus
one (FMO) staining controls. Flow cytometry plots are shown
as contour plots (5% with outliers). Overlay histograms were
normalized to mode.
Ex vivo Stimulation of CNS Cells
For intracellular cytokine detection, CNS single cell suspension
derived from naive or EAE mice was stimulated in 96 well
plates in complete medium [RPMI-1640 supplemented with
2mM L-glutamine (Gibco), 100 U/mL penicillin (Seromed),
100µg/mL streptomycin (Seromed), 10% FCS (Sigma–Aldrich)
and 1% HEPES (Gibco)] with PMA (50 ng/ml, Sigma-Aldrich)
and Ionomycin (1µg/ml, Sigma-Aldrich) and incubated together
with the cell transport inhibitor Brefeldine A (5µg/ml,
Biolegend) for 5 h at 37◦C. Cells were then stained for
surface markers, fixed and stained for cytokine detection in
permeabilization buffer.
To test degranulation capacity, CNS single cell suspension
from each individual mouse was incubated for 4 h at 37◦C
with PMA (5 ng/ml) and Ionomycin (500 ng/ml) or without
stimulants as a control to assess basal degranulation in in
complete medium in the presence of CD107a-PE (clone 1D4B;
Biolegend), cells were then stained for surface markers and
analyzed by flow cytometry.
Quantitative Real-Time PCR
A posterior quarter of the brain of perfused mice was collected,
snap frozen in liquid nitrogen and stored at −80◦C until
processing. RNA extraction was performed using a RNeasy Lipid
Tissue Mini Kit (Qiagen). Reverse transcription was performed
with MultiScribe Reverse Transcriptase (Thermofisher). RT-PCR
was prepared using TaqMan Gene Expression Assays (Cxcl9,
ID: Mm00434946_m1; Cxcl10, ID: Mm00445235_m1; Cxcl16,
ID: Mm00469712_m; Hprt, ID: Mm03024075_m1) and TaqMan
Fast Advanced Master Mix (Thermofisher) and analyzed in an
ABI Prism 7500 Real-Time PCR System instrument. Target gene
expression was normalized to the housekeeping gene Hprt. The
fold change in expression relative to naive mice was calculated
with the 2−11Ct method.
Statistical Analysis
GraphPad Prism 8 was used for statistical analysis. Statistical
difference between two independent groups was estimated with
an unpaired two-tailed Student’s t-test. Statistical difference
among more than two groups was estimated with an ANOVA.
A Shapiro-Wilk test was used to verify the normal distribution
of the data. Values of p < 0.05 were considered significant
(∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Figures show bars or
dots indicating mean ± SEM. Due to the exploratory nature of
the study, a power calculation was not performed to determine
the sample size of each group, therefore a rule of minimum
three animals to maximum eight animals per group was set for
data sampling.
RESULTS
A Fraction of NK1.1+CD27+ Cells Present
in the CNS Are CD49a+CD49b−
We previously showed that migration of mature CD11b+ NK
cells into the inflamed CNS is mediated by the fraktalkine
receptor CX3CR1 (25). In this context, we also identified
immature CD27+ NK cells in both, healthy and inflamed
mouse CNS. NK cells were identified in the CNS (brain
and spinal cord) from thoroughly perfused healthy C57Bl/6
mice as CD45highCD11b−/lowCD3−NK1.1+(Figure 1A).
This gating strategy ensured the exclusion of potentially
contaminating monocytes (CD45highCD11bhigh),
microglia (CD45lowCD11bhigh), and NKT cells
(CD3+NK1.1+) Furthermore, we confirmed that the
CD45highCD11b−/lowCD3−NK1.1+ population included all
NKp46+ cells and excluded B cells, granulocytes and basophiles,
which express the linage markers CD19, Gr-1, and FcεRIα,
respectively (Figure 1B). To further discriminate between
ILC1s and NK cells, the markers CD49a and CD49b were
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FIGURE 1 | Identification of CD45highCD3−NK1.1+ subsets in the murine CNS. (A) Gating strategy to detect NK1.1+ cells in the CNS. After doublets and dead cell
exclusion, a population that matches the size and granularity of mononuclear cells is selected, from there, the CD45highCD11b−/low population is selected to identify
the NK1.1+CD3− cells. (B) Overlayed histograms of the expression of the lineage markers NKp46, CD19, Gr-1, and FcεRIα in the CD3−NK1.1+ (solid line) and
CD3−NK1.1− (dotted line) populations of the CD45highCD11b−/low gate. Representative histograms of three mice. (C) Representative contour plots show the
expression of CD49a and CD49b in the maturation subsets of CD3−NK1.1+ cells found in the naive CNS. The numbers represent the mean percentage ± SEM of
each population (n = 6).
respectively used. Our data showed that more than 50% of
the immature CD27+CD11b− NK cells expressed CD49a and
lacked the expression of CD49b. On the other hand, the mature
(CD27+CD11b+) and fully mature (CD27−CD11b+) NK cells
were largely CD49a−CD49b+ (Figure 2). This data suggest
that a considerable fraction of the cells previously recognized
as immature NK cells present in the healthy CNS might rather
represent ILC1s.
CD3−NK1.1+ Cells of the CNS Include NK
Cells, ILC1s, intILC1s, and ex-ILC3s But
Not ILC3s
To further characterize the CD45highCD3−NK1.1+ cell subsets
of the CNS, we compared the proportion of the CD49a+
and CD49b+ populations to the spleen, a representative
lymphoid organ that contains mostly NK cells, and the liver,
a non-lymphoid organ that contains both NK and ILC1s.
Similar to the liver, about 30% of CNS NK1.1+ cells were
CD49a+CD49b− while about 60% were CD49a−CD49b+; in
addition, about 10% of the NK1.1+ cells expressed both
CD49a and CD49b (Figure 2A). As expected, most NK1.1+
cells of the spleen were CD49b+. To confirm the identity
of the identified populations in the CNS, we performed flow
cytometry analysis of the transcription factors Eomes, Tbet and
RORγt. The CD49a−CD49b+ subset expressed Tbet and Eomes,
confirming their NK cell identity; while CD49a+CD49b− cells
were Tbet+Eomes−, indicative of an ILC1 identity. Within the
CD49a+CD49b+ subset, about 50% were Eomes+, which could
represent an intermediate stage between NK and ILC1 cells as
it has been shown in the context of tumor microenvironment
and in the salivary glands (26, 27) (Figure 2B). Therefore, we
termed this population intermediate (int) ILC1s. None of the
subsets expressed RORγt discarding the presence of NCR+ ILC3s
within the identified populations. However, using the genetic
fate mapping (fm) mice for RORγt (Rorc-CreTg; Rosa26RYFP/+,
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FIGURE 2 | Transcription factor analysis of the NK1.1+ subsets of the CNS identified by CD49a and CD49b. (A) Representative contour plots showing the proportion
of CD49a+CD49b−, CD49a+CD49b+, and CD49a−CD49b+ populations in the CD45highCD3−NK1.1+ cells of the CNS, spleen and liver (n ≥ 6, performed in three
independent experiments). (B) Transcription factor expression analysis of the CD49a+CD49b−, CD49a+CD49b+, and CD49a−CD49b+ populations in the
CD45highCD3−NK1.1+ cells of the CNS. Representative contour plots of the expression of Eomes, Tbet and RORγt. Numbers indicate the mean percentage ± SEM
of each population (n = 5). (C) Analysis of the presence of RORcfm+ (YFP+) cells in the CD45highCD3−NK1.1+ cell subsets of the CNS of the RORccre; Rosa26YFP
mice. Numbers represent the mean ± SEM percentage of YFP+ cells (n = 3).
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referred as RORcfm), which permanently and heritably marks
all cells that expressed RORγt during their development, it was
found that about a quarter of the ILC1s and intILC1s were ex-
ILC3s (Figure 2C). In contrast, we found only few ILC3s in the
healthy CNS compartments of adult female RORc-GFP reporter
mice (Supplementary Figure 1). In sum, these results confirm
the existence of different group 1 ILCs in the CNS of healthy mice
that can be identified by the surface expression of the integrins
CD49a and CD49b.
CNS-ILC1s Are Distinguished From
CNS-NK Cells by Their Expression of
CD200R, CXCR6, TRAIL, and DNAM-1 and
Higher Secretion of TNF-α
We next characterized the group 1 ILCs of the CNS, contrasting
the expression of different ILC-defining markers between the
ILC1s and NK cells on the healthy mouse. IntILC1s were
excluded from the analysis because of their reduced number and
mixed transcription factor expression.
Figure 3 shows the phenotypic profile of the group 1 ILCs of
the CNS.We found that few ILC1s andNK cells expressed CD127
(24 ± 2 and 7 ± 1%, respectively), but all of them expressed
CD122. CD90.2, another prototypical ILC marker, was expressed
in great proportion by ILC1s (81 ± 4%), nonetheless, a fraction
of NKwere positive for CD90.2 (39± 4%). The majority of ILC1s
expressed the inhibitory receptor CD200R (80 ± 2%), which
is also a proposed marker to distinguish NK cells from ILC1s
(28). As expected, ILC1s homogeneously expressed the marker
of tissue residency CD69 (79 ± 2%), but they were negative
for CD103, an integrin expressed on intraepithelial ILC1s. As
expected, nor ILC1s neither NK cells expressed c-Kit. ILC1s
expressed perforin (95 ± 1%), but in a significant lower density
than NK cells (perforin gMFI ILC1s = 2,316; NK cells = 10,561;
p = 0.006). About half of ILC1s expressed CXCR3 (49 ± 4%),
while most ILC1s homogeneously expressed TRAIL (81 ± 6%),
CXCR6 (97 ± 0.8%) and DNAM-1 (96 ± 1%). NK cells did not
express TRAIL, CXCR6, and CD200R. Interestingly, DNAM-1
expression on NK cells was low while all ILC1s were DNAM-
1high. Our phenotypic profiling revealed that intILC1s share
some characteristics with ILC1s like a high expression of CD69,
Thy1.2, and TRAIL. However, compared to ILC1s, intILC1s had
a lower expression of CD200R, CXCR6, DNAM-1, and CXCR3
(Supplementary Figure 2). In sum, the phenotypical profile of
CNS CD3−NK1.1+CD49a+CD49b− cells reveal hallmark ILC1
properties that further substantiate their identity.
Modulation of CNS-ILC1 Chemokine
Receptor Expression During Autoimmune
Neuroinflammation
Next, we asked how the ILC group 1 subsets of the CNS
respond to inflammation. We first analyzed whether the markers
examined in Figure 3 are modulated in autoimmune CNS
inflammation. For that, we compared the group 1 ILCs of
the CNS of EAE mice that presented overt clinical symptoms
(score 1.5–3) with healthy controls. Of note, NK cells did not
acquire the expression of ILC1 markers or vice versa during
inflammation and both Eomes and Tbet expression remained
stable in the group 1 ILCs defined by the surface expression
of CD49a and CD49b during CNS inflammation (Figure 4A),
confirming the reliability and stability of those markers during
autoimmune inflammation. We found that the expression of
CD200R, CD69, and CD127 on ILC1s remained stable during
EAE. In concordance with their activation during inflammation,
there was an increase of CD69 expression in NK cells in EAE.
During EAE, the proportion of ILC1s that expressed TRAIL
and DNAM-1 was moderately decreased. Most striking was the
decrease in the expression of the chemokine receptors CXCR3
and CXCR6 (Figure 4C), which could reflect an internalization
of the receptor due to an ongoing ligand exposure within the
inflamed brain. Therefore, we monitored the expression of the
associated chemokines Cxcl9, Cxcl10, and Cxc16 by real time
qPCR in the brain of naive and EAEmice.Cxcl9was undetectable
in naive and preonset EAE conditions and increased at onset and
peak EAE. Similarly, Cxcl10 and Cxcl16 was detectable albeit at
low levels in naive and preonset EAE brains and dramatically
increased at onset and peak EAE (Figure 4B). These data strongly
suggest that ILC1s are able to respond to increased chemokine
gradients during CNS inflammation.
Functional Properties of CNS-ILC1s
To evaluate the functional properties of CNS-ILC1s in
comparison with CNS-NK cells on the naive mouse, we
investigated their ability to secrete IFN-γ and TNF-α after ex
vivo PMA and Ionomycin stimulation. NK cells and ILC1s
expressed IFN-γ in similar proportion. Notably, ILC1s secreted
significantly more TNF-α than NK cells. In addition, ILC1s
were also able to express both TNF-α and IFN-γ simultaneously
(Figure 5A). ILC1s provide an early source of cytokines during
acute infection (5, 28, 29), therefore we tested whether ILC1s
were differently primed to secrete cytokines at preonset, onset
and peak EAE. Interestingly, we did not observe a significant
difference in the percentage of ILC1s expressing IFN-γ and TNF-
α at different EAE stages upon ex vivo stimulation (Figure 5B).
In contrast, the proportion of cytokine expressing NK cells was
significantly higher as EAE disease progressed.
ILC1s are generally considered poorly cytotoxic. However,
we observed that in the naive CNS, all ILC1s express perforin,
though in a lower density than NK cells (Figure 6A). Moreover,
intracellular granzyme B was detected in a fraction of ILC1s
and was absent in NK cells. Interestingly, at peak EAE
we found a significant reduction of ILC1s and NK cells
expressing intracellular perforin, while the frequency of ILC1s
that expressed granzyme B increased (Figure 6A). Further, to
evaluate degranulation potential of ILC1s, we performed a
stimulation-based assay with cells derived from the CNS of
naive and peak EAE mice. CD107a surface exposure was low
in cells incubated in the absence of stimulants and increased
upon PMA and Ionomycin stimulation in both ILC1s and NK
cells of the naive CNS. However, the response to the activation
was more prominent in NK cells than in ILC1s (1 stimulated–
unstimulated) (Figure 6C). Interestingly, both ILC1s and NK
cells from the inflamed CNS showed a higher basal CD107a
surface expression in the unstimulated condition, but again,
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FIGURE 3 | Phenotypic profile of ILC1s and NK cells of the healthy CNS. Histogram overlay of NK cells (CD49a−CD49b+) (blue line), ILC1 (CD49a+CD49b−) (red
line), and FMO control (gray filled histogram) of the CD45highCD3−NK1.1+ populations of the CNS showing the expression of the indicated markers. Representative
histograms showing concatenated samples of three mice. The expression of each marker was analyzed in at least n = 4 different mice performed in at least two
independent experiments.
NK cells displayed a significant increased degranulation upon
stimulated compared to ILC1s (Figure 6D). These results show
that ILC1s respond differently than NK cells in the CNS during
autoimmune inflammation.
Location and Dynamics of CNS Group 1
ILCs During EAE
ILCs are enriched in barrier structures and the presence of ILCs
in the meninges has been reported (30). Therefore, we next
explored whether the presently described group 1 ILCs had a
preferential location within the CNS compartments.We carefully
removed the meninges and the CP from all the ventricles of
the brain and isolated the dural meninges to separately examine
the proportions of ILC1s and NK in each compartment. ILC1s,
intILC1s and NK cells were present in the three compartments.
Interestingly, a dominance on the proportion of ILC1s was
observed in all the compartments in the naive mouse with an
increase of NK cells in the EAE condition. The ILC1s were
highly enriched in the CP (about 80% of the CD3−NK1.1+
gate) while only few NK cells were found there (about 10%
of the CD3−NK1.1+ gate). The brain devoid of CP showed
also a higher proportion of ILC1s than NK cells (64% ILC1s
vs. 23% NK cells), while in the meninges, the proportion and
numbers of NK cells and ILC1s were similar (44% ILC1s vs.
35% NK cells). The proportion and numbers of intILC1s were
low in all the compartment of the healthy CNS. During EAE,
there was an increase on the numbers of ILC1s (2-fold increase)
and most notably of intILC1s (12.3-fold increase) and NK cells
(10.2-fold increase) in the brain (Figure 7A). The increased
numbers group 1 ILCs on the brain parenchyma during EAE
could point to a proliferation of these subsets in response to
neuroinflammation, therefore, we analyzed this possibility using
the whole CNS. Compared to the naive mice, the proportion of
ILC1s decreased (24.6 vs. 8.2%, p< 0.0001) while the proportion
of NK cells increased (61.6 vs. 76.3%, p = 0.04) in the CNS
during EAE (Figure 7B). When examining cell counts, it was
evident that the numbers of NK cells (identified by CD49b as
well by the transcription factors) increased during EAE. In line
with this, the analysis of proliferation with the Ki67 marker
revealed that about 50% of NK cells were actively proliferating
in the CNS during EAE, while the proportion of proliferating
ILC1s remained the same in the naïve and EAEmice (Figure 7C).
The numbers of Tbet+Eomes− cells also increased during EAE
(Figure 7B), however, a significant increase of proliferating
cells was not detected in the Tbet+Eomes− cells nor in the
intILC1s or ILC1s (Figure 7C). As the Tbet+Eomes+ cells were
the most proliferative during EAE, we also analyzed whether
within the intILC1s the Eomes+ subset proliferated more than
the Eomes− subset. We did not detect an increase on the
proportion of Eomes+ intILC1s nor a higher proportion of
Ki67+ cells in the Eomes+ intILC1s during EAE (Figure 7D).
These data indicate that NK cells, but not ILC1s nor intILC1s,
proliferate readily in the inflamed CNS and that the increased
numbers of intILC1s and ILC1s in the brain parenchyma during
inflammation might derive from an infiltration of cells from
other CNS compartments.
DISCUSSION
In this study, we characterized the ILC group 1 subsets of
the CNS and investigated their response to local autoimmune
inflammation using the EAE model of MS. We determined
that the CD45highCD3−NK1.1+ cells present in the CNS
include three different populations that can be defined by the
expression of the integrins CD49a and CD49b. We confirmed
that these populations are distinct based on the expression of the
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FIGURE 4 | Effect of neuroinflammation on the phenotype of CNS group 1 ILCs. (A) Comparison of the percentage of Tbet+Eomes+ and Tbet+Eomes− cells in the
healthy (open bars) and EAE (black filled bars) mice within the ILC1 (red), intILC1 (green), and NK (blue) subsets of the CNS (n = 5 from two different experiments). (B)
Quantitative RT-PCR analysis of genes encoding the ligands for CXCR3 (Cxcl9 and Cxcl10) and CXCR6 (Cxcl16); gene expression is presented as fold change relative
to the expression in naive brains (n = 3). (C) Graphs showing the comparison of the percentage and gMFI of markers analyzed in Figure 3 in the healthy (open bars)
and EAE (black bars) mice (n = 6 performed in two to three independent experiments). Data were analyzed with a t-test, asterisks indicate a significant difference with
a *p < 0.05, **p < 0.01, or ***p < 0.001.
transcription factors Eomes and Tbet (Figure 2B), which control
the transcriptional programs of NK cells and ILC1s, respectively
(31, 32). In addition, the analysis of the expression of signature
proteins of NK cell and ILC1s substantiate their differential
identity (Figure 3).
In our previous studies, we observed that phenotypically
mature and immature NK cells were present in the CNS
during steady state in mice. CD27 is also expressed in
ILC1s, and a closer look revealed that indeed many of the
cells recognized as immature CD27+ NK cells were rather
ILC1s (Figure 1C). A mass cytometry characterization of the
brain’s immune compartment also identified the presence of
CD45highNK1.1+CD49b+ NK cells (33), the authors showed that
these cells express CD27 and IL-2R. In concordance, we found
that both NK cells and ILC1s express CD122, which conforms
the beta subunit of the IL-2 and IL-15 receptors. We further
demonstrate that CD45highNK1.1+CD49b+ cells in the CNS
have a predominant CD11b+ expression, while this marker is
not expressed in the ILC1s (CD45highNK1.1+CD49a+CD49b−)
cells, coinciding with the known gene signature of NK cells and
ILC1s (34).
In addition to ILC1s we identified in the CNS a small (10%)
but stable population of CD49a+CD49b+ intILC1s, comparable
to the intermediary population described by Gao et al. in
the tumor microenvironment (26). Interestingly, within this
population, about 50% were Eomes+. This proportion remained
stable during neuroinflammation (Figures 4A, 7D) and differ
from ILC1s in the expression of CXCR6 and CD200R (Figure 3
and Supplementary Figure 2).
Furthermore, we found that a fraction of the ILC1s in the CNS
have an ILC3 origin as our experiments with the RORcfm mice
revealed (Figure 2C). It is therefore possible that in most tissues,
the cells recognized as ILC1s contain a fraction of ex-ILC3, as
was recently shown in the uterine ILC1s (35). In line with this,
we also found a similar percentage of ex-ILC3s in the ILC1 subset
of the liver (Supplementary Figure 1A). On the other hand, we
found very few ILC3s (about 2% of Lin− cells) in the healthy
CNS compartments of adult mice (Supplementary Figure 1B),
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FIGURE 5 | Cytokine production of CNS group 1 ILCs during EAE disease
course. (A) Representative contour plots of the expression of IFN-γ and TNF-α
in the ILC1 and NK cell subsets derived from the CNS of naive mice upon
stimulation with PMA and Ionomycin. Numbers indicate the mean percentage
± SEM of each population (n = 5). (B) Graph showing the comparison of the
percentage of cytokine expressing ILC1s (above) and NK cells (bottom) at
different EAE stages. Differences on cytokine expression between disease
stages was analyzed with a one-way ANOVA with a Bonferroni post-test
(n = 4–5, from two different experiments), *p < 0.05, **p < 0.01.
suggesting that the ILC3 source of ex-ILC3 cells found in the CNS
originates during ontogeny. It was shown in adoptive transfer
experiments that RORcfm+ ILCs adapt their phenotype to the
tissues they invade (36), for this reason we included in our
analysis the ex-ILC3s that are part of the ILC1s. On a functional
level, ex-ILC3s were found to exacerbate experimental colitis
(37). In addition, it was shown that RORcfm+ ILCs in the spleen
have a more potent anti-tumoral properties than the RORcfm−
ILCs (36). It is therefore crucial to study the plasticity and the
specific contribution of the ILC1, ILC3, and ex-ILC3 subsets
in CNS pathology. Questions we are currently addressing in
the laboratory.
Our phenotypic profile revealed that CNS-ILC1s express
hallmark markers of ILC1s in other organs, such as TRAIL,
CXCR6, CXCR3, DNAM-1, and CD200R. However, we found
that few CNS-ILC1s expressed IL-7Rα (about 30%), which
remained stable during neuroinflammation (Figures 3A, 4A)
The expression of CD127 is a defining marker of helper ILCs
(3). However, in the case of group 1 ILCs, IL-15 but not IL-
7 is required for their differentiation and maintenance (5). In
concordance, ILC1s in the liver, skin and uterus present moderate
or no expression of IL-7Rα (38).
ILC1s expressed the marker of tissue residency CD69, but they
did not express CD103, an integrin expressed in intraepithelial
ILC1s (39). In concordance with a recent report (28), we found
expression of CD200R in most ILC1s (80 ± 2%), while NK
cells did not express this marker. Notably, CD200R expression
remained stable on ILC1s during neuroinflammation, making it a
suitable candidate to identify them under different inflammatory
conditions. The ligand CD200 is expressed by endothelial cells
and neurons (40) and the blockage of the CD200R-CD200 axis
led to an aggravation of EAE disease (41), while an improved
outcome was observed when CD200R activation was enhanced
(42). Thus, CD200R+ ILC1s could also play a role in mediating
anti-inflammatory effects during neuroinflammation.
CNS-ILC1s expressed the chemokine receptors CXCR3 and
CXCR6 (Figure 3A). CXCR3 was also expressed in a fraction
of immature NK cells but CXCR6 was totally absent in NK
cells. CCR2, CCR6, and CCR7 expression was also absent
from both ILC1s and NK cells of the CNS (not shown).
Interestingly, both CXCR3 and CXCR6 became downregulated
during EAE (Figure 4A). G protein-coupled receptors can be
rapidly internalized and degraded after ligand activation. In this
line, it was shown that CXCR3 is internalized in activated T
cells after engagement with their ligands (43). Consistent with
previous reports (44, 45), we found an increase in the expression
of Cxcl9 and Cxcl10 at onset and peak EAE (Figure 4B).
CXCL16 expression has been identified in endothelial cells of
the CNS, astrocytes, microglia, and neurons (46, 47) and its
expression has been shown to be upregulated in vitro by IFN-
γ and TNF-α (46). Furthermore, an elevated concentration of
CXCL16 has been found in the CSF of MS patients (48). In
line with this, our RT-qPCR analysis revealed a low expression
of Cxcl16 in the brain of the naive mice (not shown) and an
increase at onset and peak EAE (Figure 4B). Together, these
data suggest that the decrease of CXCR3 and CXCR6 on ILC1s
during EAE may reflect an ongoing and functional activation
of these receptors. The CXCL16-CXCR6 axis has been shown to
promote neuroprotection in a model of glutamate excitotoxicity
and ischemia (47, 49). Furthermore, CXCR6+ ILC1s have been
assigned a memory function in the liver and uterus (35, 50).
Altogether, these data suggest that CNS CXCR6+CXCR3+ ILC1s
are able to home to different locations inside the CNS, where they
could mediate neuroprotective and memory functions.
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FIGURE 6 | Cytotoxic potential of group 1 ILCs in the healthy and inflamed CNS. (A) Histograms showing the expression of intracellular cytolytic proteins perforin and
granzyme B in ILC1s and NK cells present in the CNS of naive mice; representative histogram from n = 6 obtained in three independent experiments. (B) Comparison
of the percentage of ILC1s and NK cells expressing perforin and granzyme B in naive and EAE mice (n = 5–6, three independent experiments), t-test. (C)
Degranulation assay of CNS cells derived from naive mice, incubated for 4 h without stimulants or with PMA and Ionomycin in the presence of CD107a. The
percentage of CD107a+ cells in NK cells and ILC1s is shown in the left graph. At the right, the delta of the stimulated–unstimulated condition is shown (n = 6 from
three independent experiments). (D) Degranulation assay performed as (C) with CNS cells derived from EAE peak mice; n = 6 from three independent experiments;
t-test; *p < 0.05, **p < 0.01, or ***p < 0.001.
In general, helper ILC1s are known to lack cytolitic activity,
however, a cytotoxic potential of Eomes− “tissue resident NK
cells” in the context of cancer has been observed [reviewed in
(51)]. We showed that CNS resident ILC1s cells are positive
for perforin, but express it in a lower level compared to NK
cells (Figure 6A). In addition, similar to liver and salivary
gland ILCs (27, 52), CNS resident ILC1s express the apoptosis-
inducing ligand TRAIL. Interestingly, we found a slight decrease
in TRAIL expression during neuroinflammation (Figure 4C).
TRAIL can be released in a soluble form (53, 54) and it
was shown that their receptors are endocytosed together with
bound TRAIL to regulate the apoptotic signaling (55). Therefore,
the decrease in TRAIL+ ILC1s could reflect either a cleavage
to generate soluble TRAIL, or an internalization after being
bound to the death receptors in target cells. Although neurons
expressing TRAIL-R2 are susceptible to TRAIL-mediated killing
by encephalitogenic T cells (56), it has also been shown that
TRAIL has immunomodulatory effects in EAE (57, 58). A
proposedmechanism involve the lysis of autoreactive T cells (59).
In the same line, DNAM-1 has been implicated in the interaction
of NK cells with T cells via its ligand CD155, which mediates NK
cell cytotoxicity against CD4+ T cells (19). Notably, we found that
all CNS-ILC1s are DNAM-1high, and that some of them loss their
expression during neuroinflammation (Figure 4C). Based in this
observations we further explored the degranulation potential of
ILC1s in the context of neuroinflammation. Strikingly, we found
that both ILC1s and NK cells contain less intracellular perforin
during EAE (Figure 6B). At the same time, they displayed
high degranulation as shown by an increased CD107a surface
expression even in the unstimulated conditions (Figure 6D).
Therefore, the decrease in intracellular perforin could indicate
its release by active degranulation during neuroinflammation.
Furthermore, ILC1s but not NK cells expressed granzyme B,
which increased in EAE. Different kinetics of granzyme B
and perforin de novo synthesis could explain why granzyme
B increases while perforin decreases in ILC1s during EAE.
Overall, our data indicate that ILC1s of the CNS are capable
of degranulation, which, in comparison to NK cells, is however
lower upon PMA and Ionomycin stimulation (Figures 6C,D).
Taken together, our data suggest a potential role of CNS-ILC1s to
limit inflammation by interacting and lysing autoreactive T cells,
a hypothesis currently being tested in our laboratory.
It has been shown that ILC1s produce larger amounts of TNF-
α and other cytokines than NK cells (6, 38). In concordance, we
found that ILC1s stimulated ex vivo produced significantly more
TNF-α than NK cells (Figure 5A). However, contrary to models
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FIGURE 7 | Location of group 1 ILCs within CNS compartments and their dynamics during neuroinflammation. (A) Representative flow cytometry plots show the
percentages and standard error of each subset in the brain, choroid plexus and meninges in the naive and EAE mice. At the bottom, the graphs show the counts
(Continued)
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FIGURE 7 | normalized to live single cells of each subset on each compartment. Each data point represents a single brain (n = 6), for the choroid plexus and meninges
each data point represents pooled tissue from two mice. The difference between the naive and EAE condition was analyzed with a t-test; *p < 0.05, **p < 0.01, ***p
< 0.001. (B) Representative contour plots showing the mean ± SEM proportion of group 1 ILC subsets in the whole CNS of healthy and EAE mice. At the right, the
graphs show the counts normalized to the live single cell gate of each subset defined by the surface markers (left) and the transcription factors (right) (n ≥ 5 from at
least two independent experiments). (C) Graphs show the proportion of Ki67+ cells in the group 1 ILC subsets in the healthy and EAE mice, defined by the surface
markers (left) and the transcription factors (right) (n ≥ 5 from two different experiments). (D) Ratio of Eomes+/Eomes− cells within the intILC1 population in CNS from
healthy and EAE mice (right, n = 5, from two independent experiments). Percentage of Ki67+ cells in the Eomes+ and Eomes− subset of the intILC1s of EAE mice
(left, n = 6, from two different experiments). Data were analyzed with a t-test, asterisks indicate a significant difference with a *p < 0.05, **p < 0.01, or ***p < 0.001.
of acute infection (5, 28, 29, 60), we did not observed a higher
production of cytokines in ILC1s at early stages of EAE disease
(Figure 5B).
Few studies have examined the role of ILCs in EAE. Using an
antibody-mediated depleting strategy of Thy1+ ILCs, Mair and
Becher (61) showed that disease course was not affected by the
absence of ILCs. Although their focus was on Thy1+Sca+IL7-
Rα+ ILCs, their depleting strategy presumably affected all ILC
subsets including the presently described ILC1s. ILC3s were
shown to accumulate in the meninges during EAE (62). More
recently, Kwong et al. showed that in the Th17 adoptive
transfer EAE model, meningeal Tbet-dependent NKp46+ ILCs
contribute to the inflammatorymicroenvironment that promotes
Th17 cell maintenance and migration to the parenchyma (30).
We found that ILC1s reside not only in the meninges, but that
they are specially enriched in the CP (Figure 7A). The CP appears
to be involved in the initiation of the inflammation in EAE
(63) and has been proposed as a key entry gate to the CNS,
which is tightly regulated by a balance of type I and type II
interferons (64). IFN-γ-producing T cells residing in the CP
were shown tomediate licensing and gatekeeper functions during
neuroinflammation and aging (65, 66). Similarly, we anticipate
that ILC1s residing in the CP could exert a gatekeeper function,
as it was also shown for the ILCs residing in the meninges (30).
Finally, we found that the inflammatory microenvironment of
the MOG-induced active EAE did not induce the proliferation
of ILC1s but favored the proliferation of NK cells as shown by
the increased expression of Ki67 (Figure 7C). Nevertheless, the
number of ILC1s and especially of intILC1s was increased in the
brain parenchyma during EAE (Figure 7A). The increase in the
numbers of intILC1s and ILC1s could therefore derive from a cell
infiltration from the meningeal or CP compartment, a hypothesis
that is supported by the upregulation ofCxcl9,Cxcl10, andCxcl16
shown in the inflamed brain parenchyma. ANK cells recruitment
from the periphery into the CNS during inflammation has been
previously shown (25, 67, 68), we additionally demonstrate that
NK cells are able to proliferate in the CNS contributing to the
increased NK cell numbers observed in the EAE peak disease.
In sum, our data portray for the first time the characteristics of
group 1 ILCs in the CNS. The presented results strongly hint into
an immunomodulatory function of CNS-ILC1s. Further studies
should shed light into the mechanisms in which group 1 ILCs
mediate CNS homeostasis and pathology.
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